Corrigendum: Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models (Oncology Reports (2018) 40 (1545-1553) DOI: 10.3892/or.2018.6313)

Ronald A. Lubet, Vernon E. Steele, M. M. Juliana, Ann Bode, Fariba Moeinpour, Clinton J. Grubbs

Research output: Contribution to journalComment/debatepeer-review

Fingerprint

Dive into the research topics of 'Corrigendum: Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models (Oncology Reports (2018) 40 (1545-1553) DOI: 10.3892/or.2018.6313)'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science